Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Gynecologic Oncology

Breast Cancer

Multiple Myeloma

Lung Cancer

Immuno-Oncology News

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Gynecologic Oncology

Folate Receptor Alpha as a Therapeutic Target for Ovarian Cancer

Investigational data are associated with folate receptor alpha-targeting agents, with an emphasis on the recent development and therapeutic potential of antibody-drug conjugates for the treatment of patients with ovarian cancer.
Read More >>

Olaparib/Neratinib Combo Highly Synergistic in HER2+ Uterine Serous Carcinoma

Frontline Maintenance Efforts Evolve in Advanced Ovarian Cancer

PARP Inhibition Moves to Next Phase in Ovarian Cancer

Chemotherapy Remains Cornerstone of Recurrent Ovarian Cancer Treatment

Molecular Markers: From Testing to Treatment in Ovarian Cancer

View More Stories >>

View Conference Coverage

2019 State of the Science Summit on Hematologic Malignancies in Wisconsin

2019 European Lung Cancer Congress

2019 NCCN Annual Conference

2019 State of the Science Summit on Hematologic Malignancies

2019 SGO Annual Meeting

Dr. Liu on PARP Inhibitors in Recurrent Ovarian Cancer

Dr. Yadav on the Synergy of a Novel Combination in Uterine Serous Carcinoma

Dr. Ferguson on Surgical Approaches in Cervical Cancer

Dr. Leitao on Eligibility for Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

Dr. Cibula on Adding Dendritic Cell-Based Immunotherapy to Chemotherapy in Ovarian Cancer

Dr. Yadav on Olaparib/Neratinib in HER2-Overexpressing Uterine Serous Carcinoma

Dr. Essel on Repeat Use of PARP Inhibitors in Ovarian Cancer

OncLive houses thousands of videos that provide updates and information.
See more Videos

Coming Soon: Shifting Paradigms in Ovarian Cancer

Novel Agents and the Future Treatment of Ovarian Cancer

The Role of I-O in Platinum-Resistant Recurrent OC

ADC in Platinum-Resistant Ovarian Cancer

PARP Inhibitors: Which One Should We Use?

Maintenance Therapy for Recurrent Advanced Ovarian Cancer

Factors in Choice of Treatment for Recurrent Ovarian Cancer

OncLive houses thousands of videos that provide updates and information.
See more Videos

The Future Role of PARP Inhibition in Ovarian Cancer

Combinations With PARP Inhibitors for Ovarian Cancer

Ovarian Cancer: Selecting an Appropriate PARP Inhibitor

Ovarian Cancer: Treating Through Multiple Progressions

Ovarian Cancer: Comparisons Between PARP Inhibitors

Ovarian Cancer: Deciding Among PARP Inhibitors

Ovarian Cancer: Optimizing Treatment With Niraparib

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Emerging Concepts-Advanced Ovarian, Fallopian, Peritoneal, and Cervical Cancers

This discussion, led by James Tate Thigpen, MD, features the most recent information pertaining to treatment of gynecologic malignancies. The expert panel, Robert L. Coleman, MD, FACOG, FACS; Thomas Herzog, MD; Bradley J. Monk, MD, FACOG, FACS; and Angeles Alvarez Secord, MD, review the research and how to apply it in practice.View Now

Challenges for the Future of Gynecologic Cancers